Drug Profile
NV 52
Alternative Names: NV-07βLatest Information Update: 12 Dec 2017
Price :
$50
*
At a glance
- Originator Novogen
- Developer Kazia Therapeutics
- Class Anti-inflammatories; Isoflavones
- Mechanism of Action Arachidonic acid inhibitors; Nitric oxide inhibitors; Superoxide dismutase inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Inflammatory-bowel-disease in Australia (PO)
- 23 Dec 2010 NV 52 is still in phase I development for Inflammatory bowel disorders in Australia
- 10 Aug 2006 Novogen has initiated enrolment in a phase I trial for Inflammatory bowel disease in Australia